Kuznicki Law PLLC notifies investors that a class action has commenced in the United States District Courts for the Western District of Texas and Southern District of New York on behalf of shareholders of agilon health, inc. (“agilon” or the “Company”) (NYSE: AGL), if they: i) purchased or otherwise acquired the Company’s shares between April 15, 2021 and February 27, 2024, inclusive (the “Class Period”), and/or ii) purchased or otherwise acquired the Company’s shares pursuant or traceable to the Company’s April 2021 initial public offering (“IPO”), and/or iii) purchased or otherwise acquired the Company’s shares pursuant or traceable to the Company’s May 2023 secondary public offering (“SPO”).
Agilon and certain of its executives are charged with failing to disclose material information during the Class Period, violating federal securities laws.
On January 5, 2024, the Company disclosed that it was slashing its 2023 profit forecasts, specifically, lowering its 2023 Medical Margin expectation to “$340 million to $360 million, approximately $110 million below the previous guidance range…due to $90 million in higher-than-expected medical costs” and that its Chief Financial Officer, Timothy Bensley would retire and be replaced later in the year.
On this news, the price of agilon’s shares fell $3.45, or 28.6%, to close at $8.63 on January 5, 2024.
If you wish to choose counsel to represent you and the class, you must apply to be appointed lead plaintiff and be selected by the Court. The lead plaintiff will direct the litigation and participate in important decisions including whether to accept a settlement for the class in the action. The lead plaintiff will be selected from among applicants claiming the largest loss from investment in the respective securities during the class periods. Members of the class will be represented by the lead plaintiff and counsel chosen by the lead plaintiff. No class has yet been certified in the above action. Appointment as Lead Plaintiff is not required to partake in any recovery.
Shareholders have until May 20, 2024 to request that the court appoint them lead plaintiff.